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Abstract
MUC16 (CA125) belongs to a family of high-molecular weight O-glycosylated proteins known as mucins. While MUC16 is
well known as a biomarker in ovarian cancer, its expression pattern in pancreatic cancer (PC), the fourth leading cause of
cancer related deaths in the United States, remains unknown. The aim of our study was to analyze the expression of MUC16
during the initiation, progression and metastasis of PC for possible implication in PC diagnosis, prognosis and therapy. In
this study, a microarray containing tissues from healthy and PC patients was used to investigate the differential protein
expression of MUC16 in PC. MUC16 mRNA levels were also measured by RT-PCR in the normal human pancreatic,
pancreatitis, and PC tissues. To investigate its expression pattern during PC metastasis, tissue samples from the primary
pancreatic tumor and metastases (from the same patient) in the lymph nodes, liver, lung and omentum from Stage IV PC
patients were analyzed. To determine its association in the initiation of PC, tissues from PC patients containing preneoplastic lesions of varying grades were stained for MUC16. Finally, MUC16 expression was analyzed in 18 human PC cell
lines. MUC16 is not expressed in the normal pancreatic ducts and is strongly upregulated in PC and detected in pancreatitis
tissue. It is first detected in the high-grade pre-neoplastic lesions preceding invasive adenocarcinoma, suggesting that its
upregulation is a late event during the initiation of this disease. MUC16 expression appears to be stronger in metastatic
lesions when compared to the primary tumor, suggesting a role in PC metastasis. We have also identified PC cell lines that
express MUC16, which can be used in future studies to elucidate its functional role in PC. Altogether, our results reveal that
MUC16 expression is significantly increased in PC and could play a potential role in the progression of this disease.
Citation: Haridas D, Chakraborty S, Ponnusamy MP, Lakshmanan I, Rachagani S, et al. (2011) Pathobiological Implications of MUC16 Expression in Pancreatic
Cancer. PLoS ONE 6(10): e26839. doi:10.1371/journal.pone.0026839
Editor: Rakesh K. Srivastava, The University of Kansas Medical Center, United States of America
Received July 30, 2011; Accepted October 4, 2011; Published October 31, 2011
Copyright: ß 2011 Haridas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Institutes of Health (RO1 CA78590, RO1 CA131944, UO1 EDRN CA111294 and P50 SPORE
CA127297), Department of Defense (BC101014), the Susan G. Komen Foundation (KG070826), NCI Cancer Center Support Grant 5 P30 CA036727-2452 and
Nebraska Department of Health Institutional LB595 Grant for Cancer and Smoking Disease Research. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sbatra@unmc.edu

apparently altered in several malignant conditions including PC
[8].
CA125 (MUC16) is a cell surface glycoprotein that was first
identified by Bast et al in 1981[9]. MUC16 is cleaved and shed into
the bloodstream and has been the focus of active research as a
biomarker in the serum for a variety of tumor types [10]. It is
currently the only serum tumor marker routinely used in clinics for
the diagnosis and particularly predicting prognosis in ovarian
cancer patients [11]. CA125 is the best known antibody that
recognizes MUC16 both in tissues and in body fluids and is
targeted to an epitope located in the tandem repeat region of the
MUC16 protein [4,12].
Structurally the MUC16 protein comprises of an extracellular
N-terminal domain consisting of more than 22,000 amino acid
residues and is believed to be heavily glycosylated. The central
domain contains up to 60 glycosylated peptide sequences repeated
in tandem (a characteristic feature of the mucin family) followed by
a C-terminal domain containing a potential proteolytic cleavage

Introduction
Pancreatic cancer (PC) is an extremely lethal malignancy.
According to the American Cancer Society, the estimated number
of new cases and deaths due to PC in the United States in 2010
were 43,140 and 36,800 respectively with a 5 year survival rate of
6% [1]. Adenocarcinoma of the pancreatic ducts accounts for
nearly 95% of all pancreatic tumors [2] and is associated with a
median survival of only 3–6 months. The poor outlook of PC
patients is attributed in large part to the clinically silent nature of
this malignancy which often leads to its diagnosis at an advanced
and often unresectable stage of the disease.
Several proteins have been reported to be dysregulated during
the initiation and progression of PC. One such family of proteins
whose expression is aberrantly upregulated in PC is mucins. These
are high molecular weight, heavily glycosylated proteins that serve
several functions in normal tissues including lubrication and
entrapment of harmful pathogens [3–7]. Their expression is
PLoS ONE | www.plosone.org
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The grade of PanINs and MUC16 expression in each type of
PanIN lesion was assessed by the surgical pathologist (S.M.L).
The expression of MUC16 mRNA and protein was also
analyzed in a panel of PC cell lines (MiaPaca, Panc89, DanG,
HPAC, SU86.86, Colo357, CD18/HPAF, HUPT3, Capan1,
Suit2, CD11, T3M4, FG, Aspc1, Panc1, HG625, Capan2 and
BxPC3) using primers previously mentioned. The cell lines were
grown at 37uC in presence of 5% CO2 in DMEM supplemented
with 10% fetal calf serum and antibiotics (penicillin and
streptomycin 100 mg/ml). All the cell lines were obtained from
ATCC.

site, a transmembrane domain and a short cytoplasmic tail with
several potential sites of phosphorylation [13,14].
In the present study, we have analyzed the expression of
MUC16 in PC tissues and cell lines using the CA125 monoclonal
antibody. Further we have analyzed the expression of its mRNA in
tissues isolated from PC and pancreatitis patients by RT-PCR.
The overall objective of our study was to investigate whether there
is a differential expression of MUC16 during the progression and
development of PC and to examine a possible correlation between
MUC16 expression and tumor characteristics. Our study suggest
that MUC16 is not expressed in the normal pancreatic ducts but
upregulated during PC progression and development, thus
suggesting a potential role for MUC16 in PC pathogenesis and
its clinical diagnosis.

Immunohistochemistry
The slides were processed for immunostaining as described
previously [15,16]. The anti- MUC16 mouse monoclonal
antibody (M11 clone, manufactured by Dako, Carpinteria, CA,
USA) was used as the primary antibody (Stock: 764 mg/ml dilution
factor 1:500).
All stained slides were scored by a pathologist under a Nikon
E400 Light Microscope and representative photographs taken.
Staining intensity for MUC16 (CA125) was scored on a scale of 0–
3 (0-negative, 1-weak, 2-moderate, 3-strong immunoreactivity).
The percentage of cells positive for MUC16 within a given lesion
was scored on a scale of 1–4 as follows: 1: 0–25% cells positive; 2:
26–50% positive; 3: 51–75% positive; and 4: 76–100% positive.
The score of the staining intensity and the percentage of
immunoreactive cells were then multiplied to obtain a composite
score ranging from 0 to 12. A section was considered ‘‘positive’’ for
MUC16 if the intensity of MUC16 was .1. Accordingly tissues
were also classified as being ‘‘positive’’ or ‘‘negative’’ for MUC16
expression.

Materials and Methods
Ethics Statement
A written informed consent was obtained for all non-archival
tissue prior to tissue collection for all samples obtained through
UNMC.

Tissue specimen and cell lines
Fifty-eight PC and 8 normal pancreatic tissue samples (formalin
fixed and paraffin-embedded) were obtained from Accumax
(Array number A207IV). The array contained tissues classified
as non-neoplastic (8 spots), well-differentiated adenocarcinoma (12
spots), moderately differentiated adenocarcinoma (22 spots) and
poorly differentiated adenocarcinoma (24 spots). Expression of
MUC16 was analyzed by RT-PCR from 2 normal human
pancreatic tissues, 6 pancreatitis and 17 pancreatic cancer tissues
which were obtained after approval of the protocol by the IRB
(IRB- 491-97) at the University of Nebraska medical Center,
Omaha, NE. The mRNA was converted to cDNA using oligo dT
primers. The primers used to check for MUC16 expression
are MUC16_F-59 GTCCCCAACAGGCACCACACCG-39 and
MUC16_R-59GGGCACTGTTGCTGGACGTTGTATT-39 and
the PCR product was sequence verified at the UNMC DNA
sequencing facility.
Further, formalin fixed and paraffin embedded (FFPE) PC tissue
samples from 34 PC patients comprising of normal pancreas (7
spots), primary PC (31 spots) and metastasis to the liver (23 spots),
lungs (11 spots), lymph node (17 spots) and omentum/diaphragm
(11 spots) obtained from University of Nebraska Medical Center’s
rapid autopsy program (IRB-091-01) were also analyzed to
investigate the change in MUC16 expression during PC
metastasis. Under the rapid autopsy program at UNMC, tissues
from donor patients are harvested within three hours after their
death and the specimens flash frozen in liquid nitrogen or placed
in formalin for immediate fixation. Tissue microarrays (TMAs)
made from paraffin blocks of tissues from the rapid autopsy
program were used for MUC16 immunostaining. In addition to
the tumor cores, each block contained control specimens from the
non-neoplastic colon, kidney and tumor adjacent pancreas from
the same donors. The TMA blocks were cut into 4 mM sections
and mounted on charged slides.
Twenty-five PC tissue samples containing Pancreatic Intraepithelial Neoplasms (PanIN) lesions of varying grades (Number of
lesions identified-PanIN I- 163; PanIN II-197; PanIN III-26 and
normal ducts-140) adjacent to the areas of PC were also obtained
after approval of the protocol by the Institutional Review Board
(IRB-491-97) at the University of Nebraska Medical Center,
Omaha, NE. Four micron thick paraffin sections were cut and
stained with hematoxylin and eosin for pathological evaluation.
PLoS ONE | www.plosone.org

Confocal immunofluorescence microscopy
PC cells were processed for confocal microscopy as described
previously [17,18]. Briefly, cells were grown at 37uC for 48 h on
sterile glass cover slips, washed with Hanks buffer containing
0.1 M HEPES and fixed in ice-cold methanol at 20uC for 2 min.
Cells were blocked with 10% goat serum in phosphate buffered
saline (PBS) for 30 min, followed by incubation with anti-MUC16
monoclonal antibody (CA125) diluted in PBS (CA125 stock:
764 mg/ml; dilution factor 1:500) for 1 h at room temperature.
Cells were washed for 10 min (64 times) with PBS and then
incubated with FITC-conjugated goat anti-mouse secondary
antibody for 30 min. Cells were again washed (10 min 64) and
mounted on glass slides in anti-fade Vectashield mounting
medium (Vector Laboratories, Burlingame, CA, USA).

Western blot analysis
PC cell lines were processed for protein extraction and was
followed by western blotting by SDS–agarose as previously
described [17,18]. Heat denatured lysates were resolved on a
2% SDS–agarose gel by electrophoresis and subsequently
transferred on to PVDF membranes. After transfer the membrane
was blocked with 5% nonfat dry milk in PBS for 2 h, and
incubated with anti-MUC16 mAb (stock:764 mg/ml dilution
factor 1:1000) or anti-b-actin monoclonal antibody overnight at
4uC. The membranes were washed with PBS containing 0.1%
tween-20 and subsequently incubated with horseradish peroxidase- conjugated goat anti-mouse secondary antibodies (diluted
1:2000 in 5% nonfat dry milk in PBS) (Amersham Biosciences
Buckinghamshire, UK) for 1 h. The signal was detected using
enhanced chemiluminescence (ECL, Amersham Biosciences,
Buckinghamshire, UK).
2
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RNA Extraction and RT-PCR

1/1 giant cell tumor and 1/1 of mucinous cystic adenocarcinoma
expressed MUC16. Six PC patients also had a history of chronic
pancreatitis (CP). 5/6 (83%) of these tumors were also positive for
MUC16. In comparison, 7 PC patients did not have any history of
CP. Of these cases, 5/7 (71.4%) were positive for MUC16. The
expression of MUC16 was not significantly different between those
with or without a history of CP (Table 1).

Total RNA was isolated from tissues using the mirVana miRNA
isolation kit (Ambion, Foster city, CA, USA) and from cell lines
using the QIAGEN RNeasy Mini kit (QIAGEN, Valencia, CA,
USA) according to the manufacturer’s protocol. The mRNA
isolated was converted to cDNA using oligo dT primers. The
cDNA diluted 1:5 was used to determine the expression of
MUC16 mRNA using PCR according to previously described
protocol [19]. The products were run on a 1.5% agarose gel
containing ethidium bromide (10 mg/ml). The primers used to
check for MUC16 expression are those that have been previously
mentioned.

Differential upregulation of MUC16 in high grade
pancreatic dysplasia
Having observed that MUC16 is aberrantly expressed in
pancreatic ductal adenocarcinoma we next sought to study the
expression of MUC16 during the development of PC. For this, we
studied its expression in pre-malignant lesions known to precede
invasive adenocarcinoma, termed as pancreatic intraepithelial
neoplasia (PanINs). PanIN lesions are classified as PanIN I, PanIN
II and PanIN III which correspond to low, intermediate and high
grade dysplasia and are characterized by well-defined histological
changes including nuclear atypia, nuclear crowding, pseudostratification and in high grade PanINs, cribriforming [20]. We
observed that 20% of PanIN-I (33/163), 28% of PanIN-II (55/
197) and 42% of PanIN-III lesions (11/26) were positive for
MUC16 expression but its expression was not detected in the
adjacent normal ducts (n = 140) as shown in Figure 2A. MUC16
expression was significantly higher in all three stages of dysplasia
(p,0.00001) compared to the normal ducts. But MUC16
expression was significantly higher in high grade dysplasia
(PanIN-III) compared to low-grade dysplasia (PanIN-I, p = 0.02).
However, there was no significant difference in MUC16 positivity
between PanIN-I and PanIN-II (Figure 2B). Like in invasive
carcinoma, MUC16 predominantly localized to the cell membrane of the dysplastic cells.

Statistical analysis
Continuous variables (e.g.composite score) were compared
using a Student’s two-tailed t-test assuming unequal variance.
Categorical variables (stage, grade of tumor, organ of distant
metastasis) were compared using the Kruskal Wallis ANOVA test
or the Fisher’s exact test. A p-value,0.05 was considered to be
statistically significant. All statistical analysis was done using
Medcalc for Windows version 9.6.4.0 software (MedCalc software
bvba, Mariakerke, Belgium).

Results
MUC16 is differentially overexpressed in pancreatic
adenocarcinoma tissues
To identify the expression pattern of MUC16 in PC
pathogenesis, its expression was compared between non-neoplastic
ducts and pancreatic adenocarcinoma using a tissue microarray
comprising non-neoplastic pancreas (n = 8) and tissues from
primary PC of varying grades (n = 58). A tissue sample was
considered to be positive if at least .5% of the cells expressed
MUC16. MUC16 expression was not observed in the nonneoplastic ducts (Figure 1A). However, in 38/58 (65%) cases of
PC, the malignant ducts were positive for MUC16. The expression
of MUC16 was significantly higher in PC when compared to the
non-neoplastic ducts (p = 0.003 by the two-tailed Fisher’s exact
test). Further, to determine whether there is a variation in MUC16
expression with the progression of PC, we compared its expression
between PC tissues classified by tumor stage and grade. There was
a progressive increase in the expression of MUC16 with loss of
tumor differentiation, with 50% of the well-differentiated (6/12),
59% of the moderately differentiated (13/22) and 66% of the
poorly differentiated PC tissues (16/24) being positive (Figure 1A).
While the expression of MUC16 was not significantly different
between the three groups, the mean composite score was
significantly higher in moderate and poorly differentiated PC
compared to well-differentiated adenocarcinomas (p = 0.02 and
0.001 respectively). However, the composite score was not
significantly different between moderate and poorly differentiated
PC cases. This suggests that MUC16 expression increases
significantly with loss of differentiation of PC tissues.
The differential expression of MUC16 in PC was also examined
by checking the expression of MUC16 at the transcriptional level
by isolating mRNA from normal human pancreatic, pancreatitis
and PC tissues. MUC16 mRNA expression was absent in normal
pancreatic tissues (0/2, 0%) but was present in 12/17 (71%) PC
and 1/6 (16.7%) pancreatitis tissues (Figure 1B). Most of the PC
tissues were classified as moderate to poorly differentiated PC (8/
17). There was 1 case of well differentiated PC, one of
pseudopapillary neoplasm and one each of a mucinous cystic
adenocarcinoma and giant cell tumor. 5/8 (62.5%) of the
moderate-poorly differentiated, 1/1 (100%) of well differentiated,
PLoS ONE | www.plosone.org

Comparison of MUC16 expression between primary and
metastatic pancreatic cancer
Several proteins are known to have a differential expression in
primary vs. metastatic cancer [21,22]. To investigate whether the
expression of MUC16 is altered during the metastasis of PC to
distant sites, we investigated its expression in matched (obtained
from the same patient) primary pancreatic adenocarcinomas and
metastasis to the lymph nodes, lungs, liver and omentum/
diaphragm (obtained as part of the rapid autopsy program).
MUC16 was not expressed in any of the non-neoplastic ducts,
while the primary and metastatic tumors from the same patient
expressed MUC16 with nearly the same intensity. The results are
summarized in Figure 3A and 3B. There was no significant
difference in the composite score between the primary and
metastatic sites (summarized in the box plot). However, patients
who expressed MUC16 in their primary tumor also expressed
MUC16 at the metastatic sites. This suggests that pancreatic
tumors maintain MUC16 expression during their spread, possibly
pointing to the role of MUC16 in PC cell dissemination.

Expression of MUC16 in the various human pancreatic
cancer cells
Having demonstrated that MUC16 was differentially expressed
in PC tissues, we further investigated its expression in PC cell lines.
Expression of MUC16 both at the mRNA (PCR product size is
341 bp) and protein level were observed in Colo357, T3M4,
HPAF/CD18, DanG, HPAC, SU86.86, FG and Capan-1 cells
(Figure 4A and 4B). All other PC cell lines tested were negative for
MUC16 expression. To delineate the subcellular localization of
MUC16, immunofluorescence studies were performed in Capan1
3
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Figure 1. The expression of MUC16 in normal (N) and pancreatic cancer (PC) tissues by immunohistochemistry. The tissue sections
were obtained from ACCUMAX in the form of an array and were stained with anti-MUC16 monoclonal antibody. The stained sections were observed
under the microscope and the immunoreactivity was judged by the intensity and spread of the dark stain. Anti-MUC16 antibody showed no staining
in the normal pancreas tissue (both ducts and acini) while a strong staining was observed in the cancerous tissues. (A) Box plot representing the score
of MUC16 across the various grades of PC. From the box plot we observed the immunoreactivity to be higher in the poorly (D) and moderately
differentiated (C) tissues in comparison to well differentiated (B) tissues. The normal pancreas (A) tissue is also negative. Representative sections
demonstrating MUC16 expression in normal pancreatic ducts and various grades of invasive adenocarcinoma are shown. Note the predominant
membrane staining of MUC16 in PC. (B) Expression studies of MUC16 in normal, pancreatitis and pancreatic cancer tissues by RT-PCR. RT-PCR was

PLoS ONE | www.plosone.org
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performed on mRNA isolated from normal human pancreatic tissue (N1, N2), human pancreatitis tissue (Pt1–Pt6) and human pancreatic cancer tissue
(PC1–PC17). No amplification was observed in the normal tissues but amplification was observed in the pancreatic cancer and pancreatitis tissues.
Actin was used as an internal control.
doi:10.1371/journal.pone.0026839.g001

and HPAF/CD18 cells (MUC16 expressing) and SUIT2 and
CD11 (MUC16 non-expressing) cells. Staining was noted in both
the positive cell lines concordant with the distribution of MUC16
in the tissues and no staining was observed in the negative cell lines
(Figure 4C).

we examined the expression pattern of MUC16 in PC tissues and
compared it with that in the normal pancreas. Further, we also
studied its association with PC development and with tumor stage,
grade and metastasis. Interestingly, our results showed that the
normal pancreas does not express MUC16 but its expression is
significantly upregulated in 12/17 PC and 1/6 pancreatitis tissue.
It has been previously shown that there is an association between
the carcinoma of the pancreas and chronic pancreatitis (sporadic
and familial) and the standardized incident ratio of developing PC
in chronic pancreatitis patients is 14–18 [27]. This observation of
MUC16 being significantly upregulated in PC is coherent with the
expression of other membrane bound mucins MUC4 and MUC1
which are also aberrantly expressed in PC and have been
identified as potential diagnostic markers for this malignancy
[24,28–31] We also observed that MUC16 expression increased
progressively with loss of differentiation of the PC tumor. It has
been previously observed that PC patients who have been
diagnosed with distant metastasis had the tendency to have poorly
differentiated pancreatic adenocarcinoma [32,33]. Thus, our
findings suggest that MUC16 may have an important role to play
in the progression and metastasis of PC.
According to the well-known progression model for PC, ductal
carcinoma develops from non-neoplastic ducts though a series of
pre-malignant lesions termed as PanINs [33]. We observed that
MUC16 expression increases progressively from PanIN I to PanIN
III. Particularly, the percentage of MUC16 positivity in high-grade
PanIN lesions was significantly higher than that of low-grade
PanINs. This suggests that MUC16 expression is altered at the
stage of pancreatic dysplasia and may play a critical role in the
progression of PC. MUC4, another membrane bound mucin has

Discussion
PC is the fourth leading cause of cancer related deaths in the
United States with only about 20% of the patients surviving for 2
years and only 6% for five years. Its incidence to mortality ratio
has remained virtually unchanged for the past several decades
despite a considerable understanding of its biology [23,24]. This
high mortality rate among PC patients is due to the tendency of
the cancer cells to metastasize early. This, together with the poor
response to therapy and high-rate of recurrence makes it one of
the most lethal cancers known to man [24]. PC is often diagnosed
at an advanced stage, chiefly due to the lack of reliable early
diagnostic markers [24]. Therefore, there is an urgent need to
identify specific early detection marker(s) and suitable molecular
targets to combat PC. Mucins are one of the major biomarkers
that have emerged in recent years as highly specific diagnostic
markers in several malignancies including pancreatic, gynecologic
and aerodigestive tract malignancies [25]. Further, their aberrant
expression has been demonstrated to modulate cell growth,
differentiation, transformation, adhesion, invasion and immune
surveillance [7].
CA125/MUC16 is a tumor biomarker that is currently used for
the follow-up of patients with ovarian cancer [26]. However, its
role in PC pathogenesis remains unexplored. In the present study,

Table 1. Information of PC patients from whom tissues were isolated to study MUC16 expression.

Sample
Number

Age

Gender

Location of tumor
on pancreas

Tumor differentiation grade

1

73

M

Head

2

83

M

Neck

3

16

F

Tail

Solid pseudopapillary neoplasm

4

62

M

Tail

N/A

5

60

F

Head

Well differentiated

Yes

+

6

80

M

Head

Moderate to poorly differentiated adenocarcinoma

Yes

+

7

46

M

N/A

Moderately differentiated adenocarcinoma

Yes

+++

8

74

F

Body and Tail

Poorly differentiated PDAC

Yes

2

9

70

F

Head

N/A

No

2

10

58

M

Tail

Moderate to poorly differentiated adenocarcinoma

No

++

11

59

M

Tail

Giant cell tumor

Yes

++

12

35

F

Head and neck

Mucinous cyst adenocarcinoma

No

+

13

72

M

Head

Moderate to poorly differentiated adenocarcinoma

Yes

+++

M

N/A

Poorly differentiated adenocarcinoma

No

+

14

N/A

15

69

16

N/A

17

N/A

Chronic
Pancreatitis

MUC16
expression

Moderately differentiated PDAC

No

+

Moderately differentiated PDAC

No

2

No

++

2

Abbreviations: PDAC-Pancreatic Ductal Adenocarcinoma; N/A-Not Available.
doi:10.1371/journal.pone.0026839.t001
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Figure 2. Expression of MUC16 in PanIN lesions and normal ducts. (A) MUC16 expression was evaluated in tissues containing both the
normal pancreas, and adjacent dysplastic lesions. While MUC16 expression was weak in the low-grade, early stage PanIN lesions (PanIN I), it
progressively increases with increasing dysplasia with the highest expression observed in high-grade dysplasia (PanIN III) and PC. Note the
predominant membrane staining of MUC16 in all grades of PanINs (Original magnification 6200). (B) Box plot representing the composite score of
MUC16 across the different grades of PanIN lesions and normal ducts. From the box plot we observe that MUC16 is strongly expressed in PanIN II and
III when compared to PanIN I.
doi:10.1371/journal.pone.0026839.g002

during its progression [33,37] Among the several molecules
observed to play a role in the metastasis of PC cells, mucins have
emerged as one of the key determinants. We have previously
shown that MUC4, another transmembrane mucin when
expressed promotes metastasis and invasiveness in PC cells
[18,38,39]. In the present study, we observed that those primary
PCs that express MUC16 also express MUC16 with nearly equal
intensity in the metastatic sites. This suggests that PC cells may
maintain their expression of MUC16 during the metastatic
process. MUC16 has been previously demonstrated to be
important in the metastasis of solid tumors to the central nervous
system via its interaction with mesothelin, a protein differentially
expressed in normal mesothelial cells, mesotheliomas and some

been previously shown to be differentially upregulated with
progressively increasing dysplasia, suggesting the possibility that
there may be certain common regulatory pathways that modulate
the expression of both these mucins during PC development
[28,34,35]
The high mortality rate in PC patients is due to the frequent
occurrence of distant metastasis. In an analysis of 4,012 autopsies
performed on PC patients between 1914 and 1943 it was reported
that the most common site of distant metastasis was the liver,
followed by the peritoneum, lung and pleura, bones and the
adrenal glands [33,36]. But PC is not limited to these organs. Even
small PCs (,2 cm in diameter) exhibit metastasis, supporting the
premise that PC is a malignancy that metastasizes very early
PLoS ONE | www.plosone.org
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Figure 3. Expression of MUC16 in matched primary and metastatic pancreatic cancer tissues. To investigate the alteration in MUC16
expression with progression, we investigated the expression of MUC16 in matched primary pancreatic cancer and metastasis to either the lung,
lymph node, liver or the omentum/diaphragm. In (A) while the expression of MUC16 was higher in metastatic PC than in the primary tumor, this was
not significant. A- Normal pancreas; B- pancreatic cancer; C- Liver metastasis; D- Lung metastasis; E- Lymph Node metastasis; F- Omentum/Diaphragm
metastasis. Further, (B) shows that in the same patient, the non-neoplastic ducts were negative, while there was a strong expression of MUC16 in the
primary pancreatic tumor and this was maintained even in the metastasis.
doi:10.1371/journal.pone.0026839.g003

of PC will be the basis of our next study. Its upregulation, which
was particularly strong during the late stages of PC dysplasia,
suggests that the mechanisms that turn on its expression are
possibly turned on late during PC development. Studies on MUC4
mucin have revealed that its expression is silenced in normal ducts
by virtue of hypermethylation of its promoter [42,43]. Whether
similar epigenetic changes also regulate MUC16 expression
remains to be examined in future studies. The detection of
MUC16 in high-grade PanINs (considered to be the true
dysplastic lesions with a high risk for invasive cancer) suggests its

other mesenchymal malignancies [40,41]. Hence it is possible that
MUC16 might interact with mesothelin and facilitates metastasis
in PC.
The molecular mechanisms driving metastasis in PC requires a
better understanding of proteins that modulate epithelial-mesenchymal transition (EMT) and the reverse process (MET), which
are necessary for the detachment and re-attachment of tumor cells
at the site of metastasis respectively. The results of our study
suggest that MUC16 might have a role for the development and
progression of PC and studying its specific role in the progression
PLoS ONE | www.plosone.org
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Figure 4. Expression of MUC16 in a panel of PC cell lines using western blot, RT-PCR and confocal studies. (A) Western blot analysis of
MUC16 expression in PC cell lines. Protein lysates from eighteen PC cell lines were resolved on a 2% SDS-agarose gel. MUC16 expression was
observed in DanG, HPAC, SU86.86, Colo357, CD18/HPAF, Capan1 and T3M4 cell lines. b-actin was used as an internal control (B) RT-PCR analysis of
MUC16 expression in various PC cell lines. Actin was used as an internal control. (C) Immunofluorescence studies of two cell lines (CD18 and Capan1)
that expresses MUC16 and two cell lines (CD11 and SUIT2) that do not express MUC16.
doi:10.1371/journal.pone.0026839.g004

various PC cell lines screened. In addition, we also observed that
MUC16 expressing cell lines, such as Capan 1 (liver met), Colo
357 (lymph node met) and T3M4 (lymph node met) were derived
from metastatic sites while the MUC16 non expressing cell lines
such as Panc1, AsPC1 and BxPC3 were isolated from the primary
tumor site (pancreas). Further, from the RT-PCR studies we
observed that the mRNA levels of some PC cell lines did not
corroborate with their corresponding protein levels. We speculate
that MUC16 mRNA undergoes post transcriptional processing in
certain cell lines. We are currently performing preliminary studies
to further investigate this hypothesis.
In conclusion, our study shows that MUC16 is expressed only in
pancreatic adenocarcinomas when compared to undetectable
levels in the normal pancreas. The expression of MUC16 is
stronger with progressive worsening pancreatic dysplasia (from
PanIN I lesion to PanIN III). A strong expression pattern of

potential use in the early detection of potentially malignant lesions
in the pancreas. MUC16 is also shed in the bloodstream (known as
CA125), making it an attractive molecule for investigation as a
potential secreted biomarker for PC [44].
Further to identify a suitable in vitro model to investigate the
functional role of MUC16, a panel of PC cell lines was screened
for MUC16 expression both at the protein and the mRNA level.
On performing western blot analysis, it was observed that MUC16
expression either appeared as a single band or as a streaky band. It
has been previously shown that when mucins are treated with 2mercaptoethanol and analyzed on a SDS-PAGE gel, a streaky
band is obtained as the mucins have been reduced from its
oligomeric structure to its monomeric form. This monomeric form
enables mucins to migrate faster on the gel and the intact
oligomers remain in the well [45]. This thus explains the
differential expression pattern of MUC16 obtained across the
PLoS ONE | www.plosone.org
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and James R. Talaska of the Confocal Laser Scanning Microscope Core
Facility at the University of Nebraska Medical Center for providing
assistance with confocal microscopy, and the Nebraska Research Initiative
and the Eppley Cancer Center for their support of the Core Facility.

MUC16 was observed in matched primary tumors and metastatic
tumors at all the sites examined (liver, lung, lymph nodes and
omentum/diaphragm) suggesting that MUC16 could be playing
an important role in the progression and metastasis of PC.
Further, MUC16 expression was observed in several PC cell lines
at both the protein and the mRNA level. Overall, these results
suggest a potential implication of MUC16 in PC pathogenesis and
provide a basis for future studies aimed at unraveling the functions
of this large membrane bound glycoprotein in PC.
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